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Abstract
Although the formation of a covalent enzyme-cleaved DNA complex is a prerequisite 
for the essential functions of topoisomerase II, this reaction intermediate has the po-
tential to destabilize the genome. Consequently, all known eukaryotic type II enzymes 
maintain this complex at a low steady-state level. Recently, however, a novel topoisom-
erase II was discovered in Paramecium bursaria chlorella virus-1 (PBCV-1) that has 
an exceptionally high DNA cleavage activity [Fortune et al. (2001) J. Biol. Chem. 276, 
24401-24408]. If robust DNA cleavage is critical to the physiological functions of chlo-
rella virus topoisomerase II, then this remarkable characteristic should be conserved 
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throughout the viral family. Therefore, topoisomerase II from Chlorella virus Marburg-1 
(CVM-1), a distant family member, was expressed in yeast, isolated, and characterized. 
CVM-1 topoisomerase II is 1058 amino acids in length, making it the smallest known 
type II enzyme. The viral topoisomerase II displayed a high DNA strand passage activ-
ity and a DNA cleavage activity that was ~50-fold greater than that of human topoisom-
erase IIα. High DNA cleavage appeared to result from a greater rate of scission rather 
than promiscuous DNA site utilization, inordinately tight DNA binding, or diminished 
religation rates. Despite the fact that CVM-1 and PBCV-1 topoisomerase II share ~67% 
amino acid sequence identity, the two enzymes displayed clear differences in their DNA 
cleavage specificity/site utilization. These findings suggest that robust DNA cleavage 
is intrinsic to the viral enzyme and imply that chlorella virus topoisomerase II plays a 
physiological role beyond the control of DNA topology.  
The topological state of the genetic material profoundly influences a 
number of critical nuclear processes including DNA replication, tran-
scription, recombination, and mitosis (1, 2). For example, while global 
underwinding of DNA dramatically increases rates of replication, over-
winding of the double helix ahead of DNA tracking systems presents a 
formidable obstacle to replication fork progression and transcription 
(1-5). Furthermore, DNA knots and tangles that accumulate as a result 
of recombination and replication must be resolved for the two strands 
of the double helix to separate or for chromosomes to segregate during 
mitosis (1- 4, 6). 
In all living systems, levels of DNA under- and overwinding, knotting, 
and tangling are controlled by ubiquitous enzymes known as topoisom-
erases (1, 4, 7-10). Type II topoisomerases play critical roles in virtu-
ally every aspect of DNA metabolism. Although lower eukaryotes such 
as yeast and Drosophila express only a single form of topoisomerase II 
(11, 12), vertebrates require two closely related isoforms of the enzyme, 
topoisomerase IIα and IIβ (13, 14). Topoisomerase IIα is present at low 
concentrations in quiescent cells but increases dramatically during peri-
ods of cell proliferation (4, 15-19). Therefore, it is believed that this iso-
form plays fundamental roles in DNA replication and mitotic events such 
as chromosome segregation. In contrast, cellular levels of topoisomer-
ase IIβ appear to be independent of proliferative status (4, 15, 20, 21). 
Although the precise physiological functions of topoisomerase IIβ have 
yet to be defined, it is believed that this isoform is involved in a variety 
of ongoing nuclear processes. 
Type II topoisomerases control the topological state of DNA by pass-
ing an intact double helix through a transient double-stranded break that 
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they generate in a separate segment of the genetic material. To regulate 
the opening and closing of the “DNA gate” during this process, topoisom-
erase II forms covalent bonds between its active site tyrosyl residues and 
the newly generated DNA termini. These covalent enzyme-DNA com-
plexes are known as cleavage complexes (1, 4, 7, 8, 10, 22). 
Type II topoisomerases are essential to the survival of all proliferat-
ing cells. However, because these enzymes generate double-stranded 
DNA breaks as a mandatory prerequisite for the strand passage event, 
they pose a threat to genomic integrity every time they function (10, 23, 
24). Under normal circumstances, topoisomerase II opens and closes 
the DNA gate very rapidly. Thus, at any given moment, topoisomerase II-
DNA cleavage complexes are present at low levels and are tolerated by 
the cell. However, physiological conditions that increase either the life-
time or the concentration of cleavage complexes convert topoisomerase 
II from an essential enzyme to a potent cellular toxin that fragments the 
genetic material (25-29). 
Because the DNA cleavage activity of topoisomerase II has the poten-
tial to destabilize the genome, the enzyme plays a central role in cancer. 
While several widely used anticancer drugs act by increasing levels of 
enzyme-mediated DNA scission, evidence suggests that the actions of 
topoisomerase II may trigger the chromosomal breaks that initiate spe-
cific types of leukemia (26, 27, 30-43). The difference between killing ma-
lignant cells and initiating cancer probably is related to the physiologi-
cal levels of enzyme-induced DNA strand breaks. If the numbers of DNA 
breaks are sufficiently high, cells become overwhelmed and induce apop-
totic or other death pathways. Conversely, if the numbers of breaks are 
sublethal, they trigger recombination/repair pathways that under some 
circumstances generate cancer-causing chromosomal translocations. 
Due to the potentially lethal nature of the topoisomerase II-medi-
ated DNA scission reaction, low levels of DNA cleavage are character-
istic of all known eukaryotic type II enzymes (1, 4, 7, 8, 10, 22). Con-
sequently, this feature was believed to be a hallmark of this enzyme 
class. Recently, however, a novel type II topoisomerase was discovered 
that possesses a dramatically (30-50-fold) higher DNA cleavage activ-
ity. The enzyme is encoded by Paramecium bursaria chlorella virus-1 
(PBCV-1)1 (44-47). PBCV-1 topoisomerase II is significantly smaller than 
1.  Abbreviations: PBCV-1, Paramecium bursaria chlorella virus-1; CVM-1, Chlorella virus Mar-
burg-1; PCR, polymerase chain reaction; kDNA, kinetoplast DNA.   
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its eukaryotic counterpart due to a large C-terminal deletion, but oth-
erwise displays high amino acid sequence identity. Furthermore, aside 
from a robust DNA cleavage activity, the catalytic reaction of the viral 
enzyme is in all respects typical of eukaryotic type II topoisomerases. 
It is not known what role topoisomerase II plays in the life cycle of 
chlorella viruses. The extremely high DNA scission activity of PBCV-1 
topoisomerase II suggests that the viral enzyme may play alternative 
roles beyond the normal control of DNA topology, such as initiating ge-
netic recombination in the virus or death pathways in the host cell. If ro-
bust DNA cleavage is critical to the physiological functions of chlorella 
virus topoisomerase II, then this remarkable characteristic should be 
evolutionarily maintained throughout this diverse and ancient group 
of viruses (48-51). Therefore, recombinant topoisomerase II from Chlo-
rella virus Marburg-1 (CVM-1), a distantly related family member (52), 
was expressed in yeast, isolated, and characterized. CVM-1 topoisomer-
ase II displayed a DNA cleavage activity that was even higher than that 
seen for the PBCV-1 enzyme. This finding strongly suggests that the high 
DNA cleavage activity of the chlorella virus type II topoisomerases is in-
trinsic to this viral enzyme family and implies that it provides an impor-
tant physiological benefit for the virus. 
Experimental Procedures 
Enzymes and Materials. 
Negatively supercoiled pBR322 DNA was prepared using a Plasmid 
Mega Kit (Qiagen) as described by the manufacturer. Kinetoplast DNA 
(kDNA) was isolated from Crithidia fasciculata as described by Englund 
et al. (53). [γ-32P]ATP (~5000 Ci/mmol) was obtained from ICN. Etopo-
side was from Sigma, amsacrine was from Bristol-Myers Squibb, and CP-
115,953 was from Pfizer. These drugs were stored at 4 °C as 10 or 20 
mM stock solutions in 100% DMSO. The pPM231 vector used for expres-
sion of viral type II topoisomerases was the gift of Dr. Louise Prakash. 
All other chemicals were analytical reagent grade. 
Cloning of the CVM-1 Topoisomerase II Gene. 
The putative topoisomerase II ORF of 3174 base pairs was amplified 
from CVM-1 genomic DNA by the polymerase chain reaction (PCR) with 
KOD Hot Start DNA polymerase (Novagen). The following sequences 
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were used for the forward and reverse primers, respectively: TACTAAC-
GGATCCAATAAACATGGC and TATGTTTAGGATCCAATTTCAAATG. CVM-1 
genomic DNA was denatured at 94 °C for 2 min and subjected to 40 cy-
cles of PCR using the following program: denaturation at 94 °C for 15 s, 
annealing at 50 °C for 30 s, and primer extension for 4 min at 68 °C. Fol-
lowing PCR, primers were allowed to extend for an additional 10 min 
at 68 °C, and the final product was purified by gel electrophoresis. The 
pMP231 vector was digested with BglII and treated with calf intestinal 
phosphatase for 1 h. The PCR product was digested with BamHI, ligated 
into the vector, and transformed into Escherichia coli TOP10. The CVM-1 
topoisomerase II construct was sequenced to confirm the primary struc-
ture of the gene. The resultant plasmid, pPMTOP030, was transformed 
into Saccharomyces cerevisiae JEL-1Δtop1 by heat shock. The GenBank 
accession number for CVM-1 topoisomerase II is AY761524. 
Expression and Purification of Recombinant Type II Topoisomerases. 
CVM-1 topoisomerase II and PBCV-1 topoisomerase II were expressed 
in S. cerevisiae JEL-1Δtop1 and purified by a modification of the proce-
dure of Lavrukhin et al. (44). A detailed protocol for the purification of 
CVM-1 topoisomerase II is presented in the Supporting Information that 
accompanies this paper. Human topoisomerase IIα was expressed and 
purified as described by Kingma et al. (54). 
DNA Relaxation. 
DNA relaxation reactions were carried out as described by Fortune and 
Osheroff (55). Assay mixtures contained 0.05-4 nM CVM-1 topoisom-
erase II, PBCV-1 topoisomerase II, or human topoisomerase IIα, 1 mM 
ATP, and 5 nM negatively supercoiled pBR322 DNA in a total of 20 μL of 
DNA relaxation buffer (CVM-1 topoisomerase II and PBCV-1 topoisom-
erase II, 10 mM Tris-HCl, pH 8.5, 62.5 mM NaCl, 62.5 mM KCl, 0.1 mM 
NaEDTA, 2.5 mM MgCl2, and 2.5% glycerol; human topoisomerase IIα, 
10 mM Tris-HCl, pH 7.9, 175 mM KCl, 5 mM MgCl2, 0.1 mM NaEDTA, and 
2.5% glycerol). Reactions were incubated at 30 °C (CVM-1), 25 °C (PBCV- 
1), or 37 °C (human) for 15 min and stopped by the addition of 3 μL of 
stop solution (0.5% SDS, 77 mM EDTA). Proteinase K was added (2 μL 
of a 0.8 mg/mL solution), and reactions were incubated for 30 min at 45 
°C to digest the enzyme. Samples were mixed with agarose gel loading 
buffer (60% sucrose in 10 mM Tris-HCl, pH 7.9) and subjected to elec-
trophoresis in 1% agarose gels in 100 mM Tris-borate, pH 8.3, 2 mM 
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EDTA. Gels were stained for 30 min with 0.5 μg/mL ethidium bromide, 
and DNA bands were visualized by UV light and were quantified using 
an Alpha Innotech digital imaging system (San Leandro, CA). 
Decatenation of Kinetoplast DNA (kDNA). 
DNA decatenation reactions were carried out as described by Miller et 
al. (56). Assay mixtures contained 1 mM ATP, 5 nM kDNA, and 0-20 nM 
topoisomerase II in a total of 20 μL of DNA relaxation buffer. Decatena-
tion was initiated by the addition of topoisomerase II, followed by incu-
bation for 30 min at 30 °C (CVM-1), 25 °C (PBCV-1), or 37 °C (human). 
Reactions were terminated by the addition of 3 μL of stop solution. Sam-
ples were processed and products were quantified as in the preceding 
section. 
DNA Cleavage. 
Plasmid DNA cleavage reactions were based on the procedure of For-
tune and Osheroff (55). Unless stated otherwise, reaction mixtures con-
tained 10 nM negatively supercoiled pBR322 DNA in a total of 20 μL of 
DNA cleavage buffer (CVM-1 topoisomerase II, 10 mM Tris- HCl, pH 8.5, 
120 mM KCl, 0.1 mM NaEDTA, 15 mM MgCl2, and 2.5% glycerol; PBCV-1 
topoisomerase II, 10 mM Tris-HCl, pH 8.5, 62.5 mM NaCl, 62.5 mM KCl, 
0.1 mM NaEDTA, 2.5 mM MgCl2, and 2.5% glycerol; human topoisom-
erase IIα, 10 mM Tris-HCl, pH 7.9, 100 mM KCl, 5 mM MgCl2, 0.1 mM 
NaEDTA, and 2.5% glycerol). In reactions that optimized DNA cleavage 
by CVM-1 topoisomerase II, the pH, MgCl2 concentration, reaction tem-
perature, or KCl concentration was varied. DNA cleavage was initiated 
by the addition of topoisomerase II (final enzyme concentrations were 
20 nM for CVM-1 and PBCV-1 and 200 nM for human unless stated oth-
erwise). Reaction mixtures were incubated for 6 min at 30 °C (CVM-1), 
25 °C (PBCV-1), or 37 °C (human) to establish cleavage/religation equi-
libria. Cleavage intermediates were trapped by the addition of 2 μL of 
1.15% SDS and 2 μL of 115 mM NaEDTA, pH 8.0 (CVM-1 and PBCV-1), or 
2 μL of 5% SDS and 2 μL of 250 mM NaEDTA, pH 8.0 (human). Protein-
ase K was added (2 μL of 0.8 mg/mL), and mixtures were incubated for 
30 min at 45 °C to digest the type II enzyme. Samples were mixed with 
2 μL of agarose gel loading buffer, heated for 2 min at 45 °C, and sub-
jected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate, pH 
8.3, 2 mM EDTA containing 0.5 μg/mL ethidium bromide. DNA cleavage 
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was monitored by the conversion of negatively supercoiled plasmid to 
linear molecules. DNA bands were quantified by digital imaging as de-
scribed above. To determine whether DNA cleavage mediated by CVM-1 
topoisomerase II was reversible, EDTA (10 mM final concentration, in 
lieu of post-SDS addition) was added prior to treatment with SDS. To de-
termine whether cleavage was protein-linked, proteinase K treatment 
was omitted. 
DNA sites cleaved by CVM-1 topoisomerase II, PBCV-1 topoisomerase 
II, or human topoisomerase IIα were mapped as described by O’Reilly 
and Kreuzer (57). A linear 4330 bp fragment (HindIII/EcoRI) of pBR322 
plasmid DNA singly labeled with [32P]phosphate on the 5′-terminus of 
the HindIII site was used as the cleavage substrate. Reaction mixtures 
contained 0.35 nM DNA molecules and 60 nM topoisomerase II in 50 μL 
of cleavage buffer. Assays were carried out in the absence of compound 
or in the presence of 50 μM etoposide, amsacrine, or CP-115,953. Re-
actions were started by the addition of the enzyme, and the mixtures 
were incubated for 10 min at 30 °C (CVM-1), 25 °C (PBCV-1), or 37 °C 
(human). Cleavage intermediates were trapped by adding 5 μL of 1.15% 
SDS followed by 5 μL of 115 mM NaEDTA (CVM-1 and PBCV-1), or 5 μL of 
10% SDS followed by 5 μL of 250 mM NaEDTA, pH 8.0 (human), and the 
enzymes were digested with proteinase K (5 μL of a 0.8 mg/mL solution) 
for 30 min at 45 °C. Products were precipitated twice in 100% ethanol, 
dried, resuspended in 40% formamide, 8.4 mM EDTA, 0.02% bromophe-
nol blue, and 0.02% xylene cyanole FF, and subjected to electrophore-
sis in 6% acrylamide gels. Gels were fixed in 10% methanol/10% ace-
tic acid for 5 min and dried. DNA cleavage products were visualized on 
a Bio-Rad Molecular Imager FX. 
Topoisomerase II-DNA Binding. 
Topoisomerase II-DNA binding was assessed using a nitrocellulose filter-
binding assay. Linear pBR322 DNA radiolabeled with [32P]phosphate was 
prepared as described in the DNA Cleavage section. Binding mixtures 
contained 5 nM DNA and 10-400 nM topoisomerase II in a total of 20 μL 
of DNA binding buffer [10 mM Tris-HCl (CVM-1 topoisomerase II, pH 8.5; 
human topoisomerase IIα, pH 7.9), 5 mM KCl, 0.1 mM NaEDTA, and 2.5% 
glycerol] and were incubated for 6 min at 30 °C (CVM-1) or 37 °C (hu-
man). Nitrocellulose membranes (0.45 μm HA, Millipore) were prepared 
by incubation in DNA binding buffer for 10 min. Samples were applied 
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to the membranes and filtered in vacuo. Membranes were washed three 
times with 1 mL of DNA binding buffer, dried, and submerged in 8 mL of 
scintillation fluid (Econo-Safe, Research Products International). Radio-
activity remaining on the membranes was quantified using a Beckman 
LS 5000 TD scintillation counter. The percent DNA bound to topoisom-
erase II was determined by the ratio of the radioactivity on the mem-
branes vs that of the input DNA. 
DNA Religation. 
Topoisomerase II DNA religation was monitored according to the proce-
dure of Robinson and Osheroff (58). Topoisomerase II DNA cleavage/re-
ligation equilibria were established as above for plasmid DNA cleavage. 
Religation was initiated by shifting reactions from 30 °C (CVM-1) or 37 
°C (human) to –5 °C. Reactions were stopped at time points following 
the temperature shift by the addition of 2 μL of 1.15% SDS followed by 
2 μL of 115 mM NaEDTA, pH 8.0 (CVM-1), or 2 μL of 5% SDS followed by 
2 μL of 250 mM NaEDTA, pH 8.0 (human). Samples were processed and 
analyzed as described for topoisomerase II plasmid DNA cleavage reac-
tions. Religation was monitored by quantifying the loss of linear DNA. 
Results 
Because of the potentially mutagenic and lethal effects of topoisomer-
ase II-generated DNA breaks, the enzyme maintains low levels of cova-
lent DNA cleavage complexes throughout its strand passage event (1, 
10, 23). This characteristic is an invariant feature of all known eukary-
otic type II enzymes. Therefore, it was remarkable when a eukaryotic-
like topoisomerase II from chlorella virus PBCV-1 was discovered that 
displayed a DNA scission activity ~30 times higher than that of human 
topoisomerase IIα (44- 46). The extraordinary DNA cleavage activity of 
PBCV-1 topoisomerase II raises questions regarding the physiological 
role of this enzyme. 
If robust DNA cleavage is critical to the in vivo functions of chlorella 
virus topoisomerase II, then this remarkable characteristic should be 
maintained throughout the viral family (48-51). Therefore, topoisomer-
ase II from a distantly related chlorella virus, CVM-1, was characterized. 
The two viral strains differ in a number of critical aspects. CVM-1 and 
PBCV-1 infect different Chlorella species, Pbi and NC64A, respectively, 
D i c k e y  e t  a l .  i n  B i o c h e m i s t r y  4 4  ( 2 0 0 5 )        9
and will not attach to the other’s algal host (49, 52). In addition, the 
methylation states of CVM-1 and PBCV-1 DNA differ markedly. For exam-
ple, while 41.9% of the cytosines in the CVM-1 genome exist as 5-meth-
ylcytosine, only 1.9% are modified in PBCV-1 (51, 59). Finally, as deter-
mined by dot blot analysis, the topoisomerase II genes in these two viral 
strains display little cross-reactivity (45). Since CVM-1 and PBCV-1 dis-
play considerable divergence, similarities between the type II topoisom-
erases of these two viruses would imply a strong conservation over the 
course of chlorella virus evolution. 
Cloning, Expression, and Purification of CVM-1 Topoisomerase II. 
Random sequencing of the CVM-1 genome identified an open reading 
frame that was predicted to encode a protein with 67% amino acid se-
quence identity to PBCV-1 topoisomerase II (Figure 1). The putative 
CVM-1 topoisomerase II is 1058 amino acids in length as compared to 
1531 for human topoisomerase IIα. The major difference between the 
two enzymes is that CVM-1 lacks the variable C-terminal domain of eu-
karyotic topoisomerase II. The amino acid sequence of CVM-1 topoi-
somerase II is 43% identical to the first 1058 residues of human topoi-
somerase IIα (Figure 1). Finally, CVM-1 topoisomerase II is three amino 
acid residues shorter than the PBCV-1 enzyme, making it the smallest 
known type II enzyme. 
The predicted CVM-1 topoisomerase II gene was amplified by PCR 
and cloned into the galactose-inducible pMP231 expression plasmid to 
create pPMTOPO30. S. cerevisiae JEL-1Δtop1 was transformed with pPM-
TOPO30, and CVM-1 topoisomerase II was expressed and purified to 
greater than 95% homogeneity by a procedure similar to that used to 
isolate the PBCV-1 type II enzyme (see Supporting Information Figure 
S1). The electrophoretic mobility of CVM-1 topoisomerase II on dena-
turing polyacrylamide gels was consistent with the predicted molecu-
lar mass of 120 kDa. 
Catalytic Activity of CVM-1 Topoisomerase II. 
To determine whether the CVM-1 protein was a type II topoisomerase, 
its ability to catalyze double-stranded DNA passage was determined. 
First, the relaxation of negatively supercoiled plasmid molecules was 
assessed (Figure 2). The recombinant CVM-1 protein displayed a vig-
orous DNA relaxation activity that was at least 10-fold higher than that 
of human topoisomerase IIα and slightly higher than that of PBCV-1 
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topoisomerase II. This finding confirms that the CVM-1 protein is a topoi-
somerase. However, it does not establish whether it is a type I or a type 
II enzyme. While type I topoisomerases relax plasmids by making tran-
sient single-stranded DNA breaks and require no high-energy cofactor 
(9, 60-65), type II enzymes act by creating double-stranded DNA breaks 
and require ATP to carry out strand passage (10, 66-68). Since the CVM-1 
Figure 1: The amino acid sequences of CVM-1 topoisomerase II (CVM-1), PBCV-1 topoi-
somerase II (PBCV-1), and human topoisomerase IIα (human) were aligned using the 
ClustalW sequence alignment tool provided by the European Bioinformatics Institute 
(www.ebi.ac.uk/clustalw). The presumed active site tyrosyl residue of the CVM-1 en-
zyme is located at position 737. Virtually all of the amino acid residues that are highly 
conserved among eukaryotic type II topoisomerases also are present in CVM-1 topoi-
somerase II. However, the viral type II topoisomerase lacks the C-terminal domain typ-
ical of eukaryotic type II enzymes.  
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enzyme was unable to relax the plasmid in the absence of ATP, it appears 
to be a type II topoisomerase (data not shown). To further demonstrate 
that the enzyme is topoisomerase II, a second assay, DNA decatenation, 
was utilized. Since uncoupling of double-stranded DNA rings requires 
a double-stranded DNA passage event, only type II topoisomerases can 
catalyze this reaction. As seen in Figure 3, CVM-1 topoisomerase II de-
catenated kDNA at a higher rate than human topoisomerase IIα and was 
as efficient as PBCV-1 topoisomerase II. Furthermore, no decatenation 
occurred in the absence of ATP. These findings provide strong evidence 
that the CVM-1 enzyme is indeed topoisomerase II. 
Figure 2: Relaxation of negatively supercoiled pBR322 plasmid DNA by CVM-1 topoi-
somerase II (top), PBCV-1 topoisomerase II (middle), or human topoisomerase IIα (bot-
tom). DNA relaxation reactions were carried out for 15 min in either the absence of 
enzyme (DNA) or the presence of 0.05-4 nM enzyme. Ethidium bromide-stained gels 
that are representative of three independent experiments are shown. Negatively su-
percoiled DNA (form 1, FI) and nicked circular DNA (form 2, FII) are indicated.  
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DNA Cleavage Activity of CVM-1 Topoisomerase II. 
A distinguishing characteristic of PBCV-1 topoisomerase II is its extraor-
dinarily high DNA cleavage activity. To determine whether this remark-
able feature extends to a distantly related chlorella virus, the ability of 
CVM-1 topoisomerase II to cleave DNA was optimized (Supporting In-
formation Figure S2) and characterized. The CVM-1 enzyme displayed a 
robust DNA scission activity that was dramatically higher than that ob-
served for human topoisomerase IIα (Figure 4). At least 10-fold more 
plasmid was cleaved by the viral enzyme than was cleaved by an order 
of magnitude more human topoisomerase IIα. 
Figure 3: Decatenation of kDNA by CVM-1 topoisomerase II. The percent decatena-
tion was determined by quantifying minicircles that were released from kDNA net-
works by CVM-1 topoisomerase II in the presence (closed circles) or absence (closed 
squares) of ATP, by human topoisomerase IIα in the presence of ATP (open circles), 
or by PBCV-1 topoisomerase II in the presence of ATP (open squares) and is shown 
on the left. Error bars represent the standard deviation of three independent exper-
iments. The gel shown at the right is an ethidium bromide-stained 1% agarose gel 
showing kDNA decatenation in the absence of enzyme (DNA), by human topoisomer-
ase IIα (hTIIα), by CVM-1 topoisomerase II (CVM), and by CVM-1 topoisomerase II in 
the absence of ATP (-ATP). Reaction mixtures contained 4 nM enzyme. The positions 
of the kDNA networks at the origin, as well as those of the released DNA maxicircles 
and minicircles, are indicated.  
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CVM-1 topoisomerase II was covalently attached to cleaved DNA mol-
ecules (Figure 4), as demonstrated by the decreased electrophoretic 
mobility of linearized plasmids when proteinase K treatment was omit-
ted.2 Removal of the required Mg(II) by the addition of EDTA reversed 
DNA cleavage, converting linear plasmids back to negatively supercoiled 
molecules (Figure 4). This finding demonstrates that CVM-1 topoisom-
erase II remains active following DNA cleavage and that the high levels 
of scission are not due to the formation of a dead-end cleavage complex. 
2. The electrophoretic shift of the linearized plasmid DNA observed in the absence of protein-
ase K was considerably less pronounced than previously seen for DNA cleaved by other type 
II enzymes. The DNA cleavage complex generally is shifted to the gel origin due to the strong 
interaction of topoisomerase II with the gel matrix. As determined by Coomassie staining of 
the gel, CVM-1 topoisomerase II co-localized with the linearized plasmid molecules (data 
not shown). This finding confirms that the viral enzyme is covalently attached to the cleaved 
DNA. At the present time, it is not known why CVM-1 topoisomerase II displays little affinity 
for agarose gel as compared to other type II enzymes.  
Figure 4: CVM-1 topoisomerase II displays a robust DNA cleavage activity that is pro-
tein-linked and reversible. The ethidium bromide-stained agarose gel shows a 10 nM 
negatively supercoiled plasmid DNA control (DNA) and a DNA cleavage reaction car-
ried out in the presence of 200 nM human topoisomerase IIα (hTIIα) or 20 nM CVM-1 
topoisomerase II (CVM-1). To determine whether the DNA cleaved by CVM-1 topoi-
somerase II was protein-linked, proteinase K treatment was omitted (-ProK). Revers-
ibility of the cleavage reaction was determined by adding EDTA to the reaction prior 
to SDS treatment (EDTA). Double-stranded DNA cleavage converts negatively super-
coiled plasmid (form I, FI) to linear molecules (form III, FIII). The position of nicked 
circular DNA (form II, FII) also is indicated. Data are representative of three indepen-
dent experiments.  
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To further characterize the DNA scission activity of CVM-1 topoi-
somerase II, cleavage was quantified over a range of enzyme concen-
trations and compared to that of human topoisomerase IIα and PBCV-1 
topoisomerase II (Figure 5). At an enzyme:plasmid ratio of 2:1, CVM-1 
topoisomerase II cleaved approximately half of the DNA molecules. This 
stands in marked contrast to human topoisomerase IIα, which cleaved 
less than 5% of the plasmid substrate at a enzyme:plasmid ratio of 20:1. 
The DNA scission activity of CVM-1 topoisomerase II was comparable to 
or slightly higher than that of the PBCV-1 enzyme. Taken together, these 
results demonstrate that CVM-1 topoisomerase II has an intrinsic DNA 
cleavage activity that is extremely high and is at least 50 times greater 
than that of human topoisomerase IIα.  
Figure 5: DNA cleavage by type II topoisomerases. The ability of CVM-1 topoisomer-
ase II (closed circles), PBCV-1 topoisomerase II (open squares), and human topoisom-
erase IIα (open circles) to cleave negatively supercoiled pBR322 plasmid DNA was de-
termined. A range of enzyme:DNA ratios was examined at a constant concentration of 
10 nM plasmid. DNA cleavage mediated by CVM-1 topoisomerase II also is shown in the 
inset. Cleavage is expressed as the percentage of circular DNA substrate converted to 
linear molecules at equilibrium. Error bars represent the standard deviation of three 
independent experiments.  
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Site-Specific DNA Cleavage by CVM-1 Topoisomerase II. 
DNA cleavage was monitored at the site-specific level by utilizing a singly 
end labeled linear plasmid substrate. Type II enzymes, including human 
topoisomerase IIα, typically cut DNA at a limited number of prominent 
sites (Figure 6, left). Anticancer drugs such as etoposide often enhance 
Figure 6: Distribution of 
topoisomerase II-mediated DNA 
cleavage sites on a linear DNA 
substrate. A singly end labeled 4330 
bp fragment of pBR322 (1.5 nM) was 
employed. The autoradiogram at the 
left shows a DNA control (DNA) and 
cleavage in the presence of 60 nM 
human topoisomerase IIα (hTIIα),  
60 nM human topoisomerase IIα plus 
50 μM etoposide (hTIIα/Etop), 60 
nM PBCV-1 topoisomerase II (PBCV-
1), or 60 nM CVM-1 topoisomerase 
II (CVM-1). The autoradiogram at 
the right shows a DNA control (DNA) 
and cleavage in the presence of 60 
nM CVM-1 topoisomerase II with 
no drug (CVM-1) or enzyme plus 
50 μM etoposide (Etop), amsacrine 
(Amsa), or CP-115, 953 (953). Data are 
representative of three independent 
experiments.  
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DNA scission at these same sites. However, the pronounced rise in strand 
breaks induced by these agents more often results from a dramatic in-
crease in the number of sites cut by the enzyme. For example, inclusion 
of 50 μM etoposide in cleavage assays converts topoisomerase IIα from 
an enzyme that cuts DNA at a limited array of sites to one that cleaves 
at a far greater number of sequences. 
As a first step toward understanding the basis for the robust DNA 
cleavage activity of CVM-1 topoisomerase, sites of DNA scission were 
mapped. Several aspects of CVM-1 topoisomerase II-mediated DNA 
cleavage were striking (Figure 6, left). First, the viral enzyme cut DNA 
at a modest number of sites and did not display the promiscuity asso-
ciated with drug-enhanced DNA scission. Second, virtually every site 
cleaved by CVM-1 topoisomerase II had a counterpart (although usu-
ally considerably weaker) that was cleaved by human topoisomerase 
IIα. Third, despite the fact that CVM-1 and PBCV-1 topoisomerase II cut 
DNA at high levels and with a similar sequence specificity, differences 
in site utilization were observed. 
Susceptibility of CVM-1 Topoisomerase II to Anticancer Drugs. 
Of the known eukaryotic-like type II topoisomerases, the only enzyme 
that does not display a high susceptibility to anticancer agents is PBCV-1 
topoisomerase II (45). Therefore, the effects of anticancer agents on the 
DNA cleavage activity of CVM-1 topoisomerase II were assessed. Three 
structurally and mechanistically diverse compounds were employed, 
etoposide, amsacrine, and the quinolone CP- 115,953 (10, 23, 69-73). 
Whereas etoposide and CP-115,953 bind DNA poorly (if at all), amsa-
crine is a strong DNA intercalator. Furthermore, while etoposide and am-
sacrine increase levels of DNA scission primarily by inhibiting the abil-
ity of topoisomerase II to ligate cleaved molecules, CP- 115,953 appears 
to act primarily by enhancing the forward rate of scission. 
Drugs had relatively little effect on global cleavage of supercoiled plas-
mid molecules by CVM-1 topoisomerase II (data not shown). Using the 
more sensitive site-specific assay, etoposide and amsacrine enhanced 
cleavage at a limited number of sites (Figure 6, right). In contrast, no in-
crease in cleavage was observed at any site in reactions that contained 
CP-115,953 (Figure 6, right). These results suggest that low sensitivity 
to DNA cleavage-enhancing anticancer drugs is a characteristic feature 
of type II topoisomerases from chlorella viruses. 
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Binding of DNA to CVM-1 Topoisomerase II.
Several factors may contribute to the robust DNA cleavage activity of 
CVM-1 topoisomerase II. Levels of DNA cleavage can be raised by in-
creased DNA binding, enhanced rates of DNA scission, or diminished 
rates of DNA religation. 
To determine whether the high levels of DNA cleavage mediated by 
the viral enzyme are related to a greater affinity for DNA, the ability of 
CVM-1 topoisomerase II to bind linear DNA molecules was determined. 
As seen in Figure 7, the affinity of the viral enzyme for DNA appeared 
to be slightly higher (<2-fold) than that of human topoisomerase IIα. 
This minor increase in DNA binding, however, cannot account for the 
dramatic difference in the level of DNA cleavage mediated by these two 
enzymes. 
Religation of Cleaved DNA by CVM-1 Topoisomerase II. 
At the present time, no assays are available that directly measure the 
forward rate of topoisomerase II-mediated DNA cleavage. However, 
a number of topoisomerase II-targeted anticancer drugs increase 
Figure 7: Topoisomerase II-DNA binding. The percent binding of radiolabeled linear 
pBR322 DNA to CVM-1 topoisomerase II (closed circles) or human topoisomerase IIα 
(open circles) was determined by the ratio of cpm retained on a nitrocellulose filter 
vs the input amount of radioactivity. Error bars represent the standard deviation of 
three independent experiments.  
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enzyme-generated DNA breaks by inhibiting the ability of topoisomer-
ase II to religate cleaved DNA molecules (10, 23, 69, 74). Therefore, the 
rate of DNA religation mediated by CVM-1 topoisomerase II was deter-
mined (Figure 8). On the basis of the t½ for religation, the apparent first-
order rate constant for DNA religation mediated by CVM-1 topoisomer-
ase II was ~3-fold slower than that of human topoisomerase IIα. Once 
again, it does not appear that this difference can account for the ~50-
fold greater DNA cleavage observed for CVM-1 topoisomerase II. While 
differences in the ability of the viral enzyme to bind and religate DNA 
appear to contribute to the high levels of DNA scission, the above results 
suggest that the robust DNA cleavage activity of CVM-1 topoisomerase 
II is caused primarily by a greater rate of DNA scission. 
Discussion 
Recently, the first type II topoisomerase was isolated from a virus that 
infects eukaryotic cells (44). In most respects, PBCV-1 topoisomerase 
II is similar to its eukaryotic counterparts. However, the viral enzyme 
Figure 8: DNA religation mediated by CVM-1 topoisomerase II (closed circles) or hu-
man topoisomerase IIα (open circles). The DNA cleavage/religation equilibrium was 
established as described for plasmid DNA cleavage reactions, and religation was initi-
ated by shifting samples to -5 °C. The DNA cleavage observed at equilibrium for each 
enzyme was set to 100% at time zero. Error bars represent the standard deviation of 
three independent experiments.   
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displays a remarkably high DNA cleavage activity, ~30-fold greater than 
that of previously characterized type II topoisomerases (45, 46). This un-
expected finding significantly impacts the dogma that type II enzymes 
inherently maintain low levels of cleavage complexes, and led us to ask 
whether high DNA scission is unique to the PBCV-1 enzyme or is a con-
served feature of chlorella viruses. Therefore, topoisomerase II from 
CVM- 1, a chlorella virus that is distantly related to PBCV-1, was isolated 
and characterized (52). 
CVM-1 topoisomerase II is 1058 amino acids in length (3 amino acids 
shorter than the PBCV-1 enzyme), making it the smallest known type II 
topoisomerase. The enzyme displays a vigorous double-stranded DNA 
strand passage activity and cleaves DNA at levels that exceed those of 
PBCV-1 topoisomerase II. High DNA cleavage does not result from an in-
ordinately tight binding between the viral enzyme and DNA or a dimin-
ished ability to religate cleaved strands. Rather, it is suggested that high 
cleavage is caused primarily by an increase in the forward rate of DNA 
scission. These findings are consistent with the high overall catalytic ac-
tivity of CVM-1 topoisomerase II. On the basis of the above, we conclude 
that robust DNA cleavage is a fundamental property of type II enzymes 
from chlorella viruses. 
Of the known viral families that infect eukaryotic hosts, members of 
only four encode a topoisomerase of any kind (75). Three of the four, in-
cluding Phycodnaviridae (which contains the chlorella viruses) (49, 51, 
76), Asfarviridae (which contains African swine fever virus) (77, 78), 
and Iridoviridae (which contains Chilo iridescent virus) (79), have open 
reading frames that are homologous to eukaryotic type II topoisomer-
ases (75). Like chlorella virus topoisomerase II, the predicted type II en-
zymes from African swine fever virus and Chilo iridescent virus (1191 
and 1132 amino acids in length, respectively) are much smaller than eu-
karyotic topoisomerase II (77-79). The fourth virus family, Poxviridae 
(which contains vaccinia virus), encodes a type IB topoisomerase (65, 
80-82). Vaccinia topoisomerase is by far the smallest known type I en-
zyme (314 amino acids) and possesses a DNA cleavage activity that is 
both greater and considerably more site-specific than those of any other 
characterized type IB topoisomerase (65, 82-84). 
It is notable that these four viral families are believed to be “mono-
phyletic,” in the sense that they are evolutionarily related to the exclusion 
of all other viruses (75). These families all have large double-stranded 
DNA genomes that are characterized by hairpin telomeres or circularly 
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permuted ends (85-89). In addition, they encode many of the proteins 
required for viral replication, and replicate in part or entirely in the host 
cytoplasm (49, 51, 76, 87, 88, 90, 91). 
It is not known why these viruses encode their own topoisomerases. 
However, the high DNA cleavage activity of the chlorella virus type II and 
poxvirus type I topoisomerases suggest that these enzymes play a role 
in the viral life cycle that extends beyond the control of DNA topology. 
For example, it has been proposed that vaccinia virus topoisomerase is 
involved in resolving hairpin telomeres during replication (92). In ad-
dition, these enzymes may play a role in initiating viral DNA recombi-
nation or in fragmenting the host genome. Alternatively, the high DNA 
cleavage activity of chlorella virus topoisomerase II may reflect some 
unique aspect of the viral environment, such as the high DNA methyla-
tion of the CVM-1 genome. 
Finally, the high amino acid sequence identity and other properties 
shared by chlorella virus and eukaryotic topoisomerase II make CVM-1 
and PBCV-1 topoisomerase II ideal models for studying the DNA cleav-
age reaction of type II enzymes. Although topoisomerase II-mediated 
DNA scission and ligation play important roles in upholding genomic 
stability, the low DNA cleavage activity of eukaryotic type II enzymes 
has made it impossible to address many questions regarding these crit-
ical reactions (24). The extraordinarily high steady-state concentration 
of cleavage complexes maintained by chlorella virus topoisomerase II 
provides a unique tool to address these vital issues.    
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Supporting Information 
Supporting information details the procedure used to isolate recombinant CVM-1 topoi-
somerase II. A silver-stained SDS-polyacrylamide gel containing purified recombinant 
CVM-1 topoisomerase II, PBCV-1 topoisomerase II, and human topoisomerase IIα is in-
cluded in the supporting information as Figure S1 to demonstrate purity of the sam-
ple. Also, optimization of the MgCl2 concentration, temperature, pH, and KCl concen-
tration for DNA cleavage mediated by CVM-1 topoisomerase II is shown in Figure S2. 
This material follows the References.  
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Purification of CVM-1 Topoisomerase II. Enzyme purification was carried out by a
modification of the protocol of Lavrukhin et al. (44). All steps were carried out at 4 °C. Cells
from 2-Liter yeast cultures were centrifuged for 10 min at 4,000 g, resuspended in 35 mL of
buffer A (15 mM sodium phosphate, pH 6.8, 500 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM
EGTA, 0.5 mM DTT, 0.2 mM PMSF, 1 µg/mL pepstatin, 1 µg/mL leupeptin), and disrupted by
bead beating. Cell debris was removed by centrifugation at 20,000 g for 10 min. Nucleic acids
were precipitated by the slow addition of 5% (w/v) polyethylenimine (Sigma) to the
supernatant, with stirring to 0.1% final concentration. Stirring was continued for 30 min after all
the polyethylenimine was added. The suspension was centrifuged at 20,000 g for 10 min, the
pellet was resuspended, and (NH4)2SO4 was added slowly with stirring to the supernatant to
35% saturation. The suspension was stirred for an additional 30 min and precipitated proteins
were removed by centrifugation at 20,000 g for 30 min. (NH4)2SO4 was added slowly to the
supernatant to 65% saturation, and the suspension was stirred for 30 min and centrifuged as
above. Precipitated proteins were resuspended in the volume of buffer B (25 mM sodium
phosphate, pH 6.8, 10% glycerol, 0.5 mM DTT, 0.1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL
pepstatin) required to produce the equivalent of 0.2 M residual (NH4)2SO4.
Resuspended proteins were applied to a 20 mL hydroxylapatite column (1.5 cm diameter)
that had been equilibrated with buffer C (15 mM sodium phosphate, pH 6.8, 200 mM potassium
phosphate, pH 6.8, 10% glycerol, 0.5 mM DTT, 0.1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL
pepstatin). The column was washed with three volumes of buffer C and protein was eluted with a
100 mL linear salt gradient from 200 to 750 mM potassium phosphate in buffer C.  Fractions
(1.8 mL) were collected and checked for the presence of a 120 kDa protein band by SDS-
polyacrylamide gel electrophoresis. Appropriate fractions were pooled, diluted with buffer D
3
(15 mM sodium phosphate, pH 6.8, 1 mM EDTA, 1 mM EGTA, 0.5 mM DTT) to a final
potassium phosphate concentration of <200 mM, and applied to a phosphocellulose column (1
mL, 0.7 cm diameter) that had been equilibrated in buffer D that contained 200 mM NaCl.
CVM-1 topoisomerase II was eluted with buffer D that contained 750 mM NaCl. Glycerol was
added to a final concentration of 10% (w/v), and CVM-1 topoisomerase II was aliquoted and
stored in liquid nitrogen. Protein concentrations throughout the purification were determined by
absorbance at 595 nm, using the Bio-Rad Bradford assay kit. For all assays requiring enzyme
dilution, CVM-1 topoisomerase II was freshly diluted in buffer D containing 200 nM NaCl and
40% glycerol.
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FIGURE S1. CVM-1 topoisomerase II preparation. Samples (1.5 µg) of purified recombinant
CVM-1 topoisomerase II (CVM-1), PBCV-1 topoisomerase II (PBCV-1), and human
topoisomerase IIα (hTIIα) were subjected to electrophoresis on a 7.5% denaturing SDS-
polyacrylamide gel and visualized with silver stain. Arrows indicate the electrophoretic mobility
of 200 and 120 kDa molecular weight standards.
FIGURE S2. Optimization of DNA cleavage mediated by CVM-1 topoisomerase II. The effects
of Mg(II) (A), temperature (B), pH (C), and salt (D) on the cleavage of plasmid DNA by CVM-1
topoisomerase II are shown. Cleavage is expressed as the percentage of circular DNA substrate
converted to linear molecules at equilibrium.
5
200 kDa
120 kDa
1 2 3
C
V
M
-1
P
B
C
V
-1
hu
m
an
αααα
6
0
1 0
2 0
3 0
4 0
5 0
D
N
A
 C
le
av
ag
e 
(%
)
0 5 0 100 150
[Mg2+] (mM)
0
1 0
2 0
3 0
4 0
5 0
D
N
A
 C
leavage (%
)
0 1 0 2 0 3 0 4 0 5 0
Temperature (˚C)
0
1 0
2 0
3 0
4 0
5 0
D
N
A
 C
le
av
ag
e 
(%
)
6 .5 7 7.5 8 8.5 9 9.5 1 0
 pH
0
1 0
2 0
3 0
4 0
5 0
D
N
A
 C
leavage (%
)
0 5 0 100 150 200 250
[KCl] (mM)
A B
C D
FIGURE S2
